"Independently owned, radically transparent." That is the pitch on half the skincare launches in my inbox, and this year it comes with a number attached. NielsenIQ, in an analysis it published in late January, says indie beauty brands grew dollar sales 22.3 percent over the prior year, against 6.1 percent for the conglomerates that used to own the shelf. In facial skincare the gap is wider still: 23.2 percent for the indies, 3.1 percent for the majors. Almost eight times faster. The small brands still hold only 32 percent of total category dollars, so this is a story about momentum, not about who is winning yet. But momentum is what the buyers price.
NielsenIQ defines an indie as a brand under 300 million dollars in annual revenue, independently owned, not part of a multi-brand group. The figures are US retail measurement, a 125 billion dollar market over the 52 weeks ending November 1, 2025, a detail, left off NielsenIQ's own write-up, that Beauty Independent surfaced from the underlying panel, so read "global" as the trend and "American" as the data. A year earlier the same panel had indies at 16.1 percent growth and conglomerates at 7.4. The gap did not just persist, it widened, and it widened partly because the majors slowed down.
Fragrance grew faster than skincare in absolute terms, 46.3 percent for indies against 11.4 for the majors, but skincare is where the ratio is widest, almost eight times faster. It is worth asking why here rather than, say, in shampoo. Three reasons hold up. Discovery moved online, where the small brands live: NielsenIQ puts 70 percent of indie sales on e-commerce against 48 percent for beauty overall, and online is growing 22 percent while stores grow 2. Skincare also rewards the thing indies do cheaply and majors do slowly, which is talk about ingredients. A founder can post a percentage and a mechanism the afternoon a trend breaks. And the launch clock is shorter: a small brand can reformulate and ship in the time a conglomerate spends in legal review.
The middle reason needs a caveat, because "ingredient transparency" is itself a marketing surface. A full INCI list on the website and a number on the front of the box is a claim like any other claim, and it still does not tell you the concentration of the one active doing the work, or who paid for the study behind the asterisk. Transparency has become a texture brands apply, the way "clinical" is a texture. It sells better than it informs. What is genuinely different is not that indies are more honest. It is that they answer faster, in the register the audience already trusts.
The most telling number in the whole analysis is not a growth rate. NielsenIQ's Anna Mayo, its vice president for the beauty vertical, notes that 62 percent of indie dollar growth comes from more shopping trips, while 64 percent of conglomerate growth comes from price increases. Read that twice. The small brands are growing because more people are buying more often. The big ones are growing because they are charging more for the same thing. One of those is demand. The other is a spreadsheet.
So the majors have a problem they cannot price their way out of, and their answer is the oldest one in this industry: if you cannot out-innovate them, buy them. In June 2025 L'Oreal took a majority stake in Medik8, the British clinical-skincare brand built on its Crystal Retinal line. Neither side disclosed terms, but Beauty Independent put the enterprise value at around one billion euros, roughly 13 times the brand's prior-year sales, and headlined the deal "science over social media buzz," which is generous framing for a company that could have hired chemists and built the line itself, and chose to write a check instead.
Put that check next to another. In May 2025 e.l.f. Beauty agreed to buy Hailey Bieber's Rhode for up to a billion dollars, closing in August at 897.5 million. Rhode did 212 million in net sales in the year to March 2025, direct to consumer, off a famously short product range. That is a revenue multiple around 4.7 on the up-to-a-billion headline, or about 4.2 on the price it actually closed at, either way no more than about a third of what Medik8 fetched. Two roughly billion-dollar skincare deals, and the price gap is the whole lesson: L'Oreal paid a science premium for a formulation story, e.l.f. paid an audience premium for a founder's reach. The one honest number in each deal is the multiple, and the multiple tells you exactly what the buyer thought it was short of. Neither built the thing. Both bought it. This is the same reflex that had e.l.f. buy the skincare brand Naturium for 355 million back in 2023.
Before anyone crowns the insurgents, the analysis also names their ceiling. The big brands keep their customers better, and the indies get discovered and dropped. NielsenIQ scores this on a loyalty measure, roughly how often the average shopper comes back to the same brand across the 52 weeks: conglomerates land at 13.2, indies at 8.8, a 4.4-point gap. Getting discovered is cheap. Getting bought again is not. The majors still hold 2 to 3 times the shelf space, 2.6 times in facial skincare specifically. And aggregate category growth is not brand health: the market can grow while the average brand's slice shrinks. A 23 percent skincare number does not mean your favorite small label is thriving. It means the category is, and that the buyers are shopping.
The growth is real, the transparency is mostly a register rather than a rigor, and the giants have read the same NielsenIQ analysis you just did. When a conglomerate pays 13 times sales for a retinal brand, it is not conceding that the indie built a better molecule. It is conceding that it lost the argument about who gets believed, and that belief is now the expensive part. You can buy the brand. The multiple is what you pay for not having built the trust yourself.
